中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 肝脏, 2019, 24(9): 975-983.
| [1] https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1377614074. [2] 中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识. 中华肝脏病杂志,2002,10:327-328. [3] Guyatt GH, Oxman AD, Vist GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.BMJ, 2008,336:924-926. [4] Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med,2017, 377:2296-2297. [5] Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology,1981,1:431-435. [6] Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology,1994,19:1513-1520. [7] Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol,1995,22:696-699. [8] Goodman ZD.Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol,2007,47:598-607. [9] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology,1996,24:289-293. [10] 田爱平,杨永峰. 慢性肝炎病理学分级分期评分系统比较. 临床肝胆病杂志,2018,34:2271-2277. [11] Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.Hepatology,2017,65:1438-1450. [12] Wang Y, Vincent R, Yang J, et al. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology, 2017, 65: 1891-1903. [13] Rousselet MC, Michalak S, Dupré F,et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology, 2005, 41:257-264. [14] Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36(suppl):S57-64. [15] Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem, 2004, 50:1344-1355. [16] 中国门静脉高压诊断与监测研究组,中华医学会消化病学分会微创介入协作组,中国医师协会介入医师分会急诊介入专业委员会, 等. 中国肝静脉压力梯度临床应用专家共识(2018版). 中华肝脏病杂志,2018, 26: 801-812. [17] Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol, 2009, 6:573-582. [18] Qi X, Berzigotti A, Cardenas A,et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol, 2018, 3: 708-719. [19] 张启迪,陆伦根. 无创肝纤维化/肝硬化评估技术的现状. 中华肝脏病杂志,2018,26:325-327. [20] Bellan M, Castello LM, Pirisi M. Candidate biomarkers of liver fibrosis: a concise, pathophysiology-oriented review.J Clin Transl Hepatol,2018,6:317-325. [21] Dong XQ, Wu Z, Zhao H, et al. "Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat, 2019,26: 297-307. [22] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology,2003,38:518-526. [23] Sterling RK, Lissen E, Clumeck N,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology,2006,43:1317-1325. [24] Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 2001,357:1069-1075. [25] Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology,2002,36(4 Pt1):986-992. [26] Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology,2005,42:1373-1381. [27] Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model.Hepatology,2005,42:1437-1445. [28] Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol,2010,25:1569-1577. DOI: 10.1111/j.1440-1746.2010.06383.x. [29] Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol,2005,100:616-623. [30] Rosenberg WM, Voelker M, Thiel R,et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 2004, 127:1704-1713. [31] Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology,2004,39:1239-1247. [32] Singh S, Muir AJ, Dieterich DT, et al. American gastroenterological association institute technical review on the role of elastography in chronic liver diseases. Gastroenterology, 2017,152:1544-1577. [33] Lin YS. Ultrasound evaluation of liver fibrosis. J Med Ultrasound, 2017,25:127-129. [34] Horowitz JM, Venkatesh SK, Ehman RL, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY),2017,42(8):2037-2053. [35] Lim JK, Flamm SL, Singh S, et al. American gastroenterological association institute guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology, 2017,152:1536-1543. [36] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版). 中华肝脏病杂志,2019,27:182-191. [37] Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol,2015,30:756-762. [38] Chen YP, Liang XE, Dai L, et al. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis, 2012, 44: 61-66. [39] Chen YP, Liang XE, Zhang Q, et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B. J Gastroenterol Hepatol, 2012, 27: 1219-1226. [40] Liang X, Xie Q, Tan D, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study. J Viral Hepat, 2018, 25: 296-305. [41] Dong XQ,Wu Z, Li J, et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study. J Gastroenterol Hepatol,2019,34: 755-763. [42] Afdhal NH, Bacon BR, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol, 2015, 13(4): 772-779,e1-3. [43] Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: a multicentre, retrospective study. Liver Int, 2015, 35: 2246-2255. [44] Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016, 63: 1817-1827. [45] Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17: 156-163, e2. [46] Thiele M, Detlefsen S, Sevelsted M?ller L, et al. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology, 2016, 150: 123-133. [47] Wu S, Yang Z, Zhou J, et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int, 2019, 13(1):91-101. [48] Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol, 2015, 13:440-451,e6. [49] Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology, 2016, 150:626-637, e7. [50] Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis, 2016, 36(1):87-98. [51] Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis, 2015, 35:184-198. [52] Campana L, Iredale JP. Regression of liver fibrosis . Semin Liver Dis, 2017, 37:1-10. [53] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet,2013, 381:468-475. [54] Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. Lancet Gastroenterol Hepatol, 2016, 1(4):328-340. [55] Weiskirchen R. Hepatoprotective and anti-fibrotic agents: It’s time to take the next step. Front Pharmacol, 2016, 6: 303. [56] Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol, 2018, 12:1143-1152. [57] 中华医学会感染病学分会,肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识.中华肝脏病杂志,2014,22:94-103. [58] Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steato-hepatitis. Clin Gastroenterol Hepatol,2017,15:1940-1949,e8. [59] Goel A, Kim WR.Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis. 2018;22:563-578. [60] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet,2015,385(9972):946. [61] Lieber CS, DeCarli LM, Mak KM, et al. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepa-tology,1990,12:1390-1398. [62] 杨瑞华,李芹,陈玮.扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化疗效的Meta分析.中华肝脏病杂志,2015,23:295-296. [63] 苗亮、杨婉娜、董晓琴,等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率. 中华肝脏病杂志, 2019,27:521-526. [64] 蔺武,刘心娟,魏南,等. 复方鳖甲软肝片抗肝纤维化疗效的系统评价. 胃肠病学和肝病学杂志,2007,16:69-72. [65] Yue HY, Yin C, Hou JL, et al. Hepatocyte nuclear factor 4 alpha attenuates hepatic fibrosis in rats. Gut, 2010, 59:236-246. [66] Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut, 2015, 64:830-841. [67] Torok NJ, Dranoff JA, Schuppan D, et al. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference. Hepatology, 2015, 62:627-634. [68] Wang Y, Liang X, Yang J, et al. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat, 2018, 25: 598-607. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
